Authors

Latest:

Dr. Kalogera on Bowel Preparation Following Minimally Invasive or Open Hysterectomies

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

Eleftherios P. Mamounas, MD

Latest:

Dr Mamounas on Surgical De-Escalation Strategies in HER2+ Breast Cancers

Terry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.

Eleftherios P. Mamounas, MD, University Florida

Eleftherios (Terry) P. Mamounas, MD

Latest:

Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer

Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.

Elena Lukina, MD

Latest:

Dr. Lukina Discusses Timely Gaucher Disease Diagnosis

Dr. Elena Lukina Discusses Timely Gaucher Disease Diagnosis

Elena S. Ratner, MD, Yale University School of Medicine

Eleni Andreopoulou, MD

Latest:

Dr. Andreopoulou on the Impact of Immunotherapy in TNBC

Eleni Andreopoulou, MD, associate professor of clinical medicine, Weill Cornell Medical College, associate attending physician, NewYork-Presbyterian Hospital, discusses shifts in the treatment paradigm of metastatic triple-negative breast cancer (TNBC) and the impact immunotherapy has had in the field.

Eleonora Teplinsky, MD

Latest:

Antibody-Drug Conjugates and T-DM1

Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 20% to 25% of breast cancers, as represented by amplification of the HER2 gene and/or HER2 protein overexpression

Elham Nasri, MD

Latest:

Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in Osteosarcoma

Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.

Eli L. Diamond, MD

Latest:

Dr. Diamond on the Ability to Test Urine for BRAF Mutations

Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis that examined the detection of BRAF mutations in urine and plasma cell-free DNA in patients with Langerhans Cell Histiocytosis(LCH) and Erdheim-Chester Disease (ECD) who have a BRAFV600E mutation

Elias J. Jabbour, MD, MD Anderson

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Elias Jabbour, MD

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.

Elias Jabbour, MD, MD Anderson Cancer Center

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Elias Obeid, MD, MPH

Latest:

Dr. Obeid on the KATHERINE Trial in HER2-Positive Breast Cancer

Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.

Elihu Estey, MD, University of Washington School of Medicine Seattle

Elihu H. Estey, MD

Latest:

Dr. Estey Discusses the FDA Approval Process

Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, discusses a potential change to the FDA approval process as it relates to Mylotarg (gemtuzumab ozogamicin).

Elisa K. Chan, MD

Latest:

Dr. Chan on Improving Mammography Screening Rates With Signed Letters

Elisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.

Elisa Krill-Jackson, MD

Latest:

Beyond Hyperglycemia: Complete Safety Management for PI3K Inhibitor Combinations

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute

Latest:

Practical Application of PARP Inhibitors in Metastatic CRPC

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Elisabeth Weiss, MD

Latest:

Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer Center

The Department of Radiation Oncology at Virginia Commonwealth University Massey Cancer Center has long been at the forefront worldwide in the development of various radiation therapy technologies that are now considered standard and have become widely available.